United Therapeutics Corporation
UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exerciseā¦ read more
Healthcare
Biotechnology
27 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$506.82
Price+1.78%
$8.85
1Y
Price
Market Cap
$21.513b
Large
Price/Earnings 3y Avg5y Avg
18.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+48.0%
EBITDA Margin+42.5%
Net Profit Margin+26.3%
Free Cash Flow Margin+48.0%
EBITDA Margin+42.5%
Net Profit Margin+26.3%
Free Cash Flow MarginRevenue
$3.155b
-0.9%
1y CAGR+11.1%
3y CAGR+13.4%
5y CAGREarnings
$1.311b
-1.8%
1y CAGR+10.4%
3y CAGR+16.7%
5y CAGREPS
$27.91
+0.2%
1y CAGR+12.5%
3y CAGR+17.4%
5y CAGRBook Value
$6.400b
$7.220b
Assets$819.800m
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
$1.093b
+5.0%
1y CAGR+15.3%
3y CAGR+14.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company